Menin-MLL inhibitor-22
Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between menin and mixed lineage leukemia (MLL) (IC50=7 nM) . Menin-MLL inhibitor-22 binds menin protein and inhibits cancer cell growth (MV4 cells, IC50=0.3 μM) . Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome) [1].
Product Specifications
CAS Number
[2851841-61-5]
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/menin-mll-inhibitor-22.html
Purity
99.85
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=C(N2CC(CN3CCC(NC4=NC=NC5=CC=C(N=C54)OCCN(C)C)CC3)C2)C=C1)(C6CC6)=O
Molecular Formula
C29H39N7O3S
Molecular Weight
565.73
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Browse additional items from our catalog
APITD1 (Apoptosis-inducing, TAF9-like Domain 1, CENP-S, CENPS, MGC32686) (MaxLight 405) discontinued
SDPR (Serum Deprivation-response Protein, CAVIN2, Cavin-2, PS-p68, Phosphatidylserine-binding Protein, SDR)
SDPR (Serum Deprivation-response Protein, CAVIN2, Cavin-2, PS-p68, Phosphatidylserine-binding Protein, SDR)
